A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Summary

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Timeline

Start

2024-06-24

Primary completion

2025-06-02

Completion

2025-06-02

Outcome

Met primary endpoint

paper Bioequivalence was demonstrated between capsules and dose-adjusted tablets across all six doses. PMID 41994902 ↗

paper The 90% confidence interval of the ratios of the geometric least-squares means of AUC0-24,ss and C max,ss between each capsule dose and corresponding tablet dose met the predefined criteria for bioequivalence. PMID 41994902 ↗

Publications

• Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. 2026 Jul;28(7):5803-5809. doi: 10.1111/dom.70783. Epub 2026 Apr 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orforglipron	Small molecule	0.8 mg	Oral
Subject	Orforglipron	Small molecule	1 mg	Oral
Subject	Orforglipron	Small molecule	2.5 mg	Oral
Subject	Orforglipron	Small molecule	3 mg	Oral
Subject	Orforglipron	Small molecule	5.5 mg	Oral
Subject	Orforglipron	Small molecule	6 mg	Oral
Subject	Orforglipron	Small molecule	9 mg	Oral
Subject	Orforglipron	Small molecule	12 mg	Oral
Subject	Orforglipron	Small molecule	14.5 mg	Oral
Subject	Orforglipron	Small molecule	17.2 mg	Oral
Subject	Orforglipron	Small molecule	24 mg	Oral
Subject	Orforglipron	Small molecule	36 mg	Oral

Indications